Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
China builds frameworks for brain-computer interface implantables, generative AI gets FDA and MHRA attention, and three more key medtech policy focus areas in July and August.
In the ALLEVIATE-HF clinical trial, continuous monitoring provided by Medtronic’s insertable cardiac monitor revealed a substantial burden of previously unsuspected arrhythmias in patients with both HFrEF and HFpEF—many of whom would not ordinarily qualify for an implantable cardiac device.
Medtech investing has maintained its momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook. Excerpted from our recent feature, “As Dollars Chase AI Dream, Investors Stay Grounded.”